Observational study to evaluate safety and efficacy of fix dose combination of Metformin, glimePiride, and voglibose in Type 2 diabetes mellitus patients
Not Applicable
- Conditions
- Health Condition 1: E118- Type 2 diabetes mellitus with unspecified complications
- Registration Number
- CTRI/2019/01/017128
- Lead Sponsor
- Aprica Healthcare Pvt Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Patients willing to provide written informed consent at the time of enrolment
2.Male or Female patients above 18 years
3.Patients suffering from type 2 diabetes mellitus
4.Patients treated with fixed dose combination metformin, glimepiride and voglibose
Exclusion Criteria
1.Patients receiving any other antidiabetic agent other than mentioned in inclusion criteria
2.Patients suffering from any other type of Diabetes except Type 2 diabetes mellitus
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of <br/ ><br>1.Reduction in Fasting Blood Glucose (FBG) <br/ ><br>2.Reduction in Post Prandial Blood Glucose (PPBG) <br/ ><br>3.Reduction in HbA1C <br/ ><br>4.Complications of Type 2 Diabetes <br/ ><br>Timepoint: 3 months
- Secondary Outcome Measures
Name Time Method Evaluation of following parameters <br/ ><br>1.Demographic data of study participants <br/ ><br>2.Comorbid conditions <br/ ><br>3.Preferred Dose of Treatment <br/ ><br>4.Dosage frequency <br/ ><br>5.Administration time <br/ ><br>6.Concomitant medications <br/ ><br>7.Adverse events <br/ ><br>Timepoint: 3 months